[{"id":6146,"regimens":[{"id":11643,"duration":{"id":5687,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":8513,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11643},{"id":8514,"answer":"In a novel combination with another drug","answer_other":"","regimen":11643}],"created":"2020-09-29T17:49:42.797302Z","updated":"2020-10-04T23:52:09.659578Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6146},{"id":11644,"duration":{"id":5688,"approximate_duration":null,"dates_unknown":false},"drug":{"id":5711,"name":"Adalimumab","url":"cure-api2.ncats.io/v1/drugs/5711","rxNorm_id":null,"notes":null},"use_drug":[{"id":8515,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11644},{"id":8516,"answer":"In a novel combination with another drug","answer_other":"","regimen":11644}],"created":"2020-09-29T17:49:42.805391Z","updated":"2020-10-04T23:52:09.666184Z","dose":"40 mg","frequency":"","route":"Subcutaneously","severity":"Inpatient","severity_detail":"","comments":null,"report":6146}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8056,"answer":"Clinical assessment","answer_other":"","report":6146},{"id":8057,"answer":"Imaging","answer_other":"","report":6146},{"id":8058,"answer":"PCR","answer_other":"","report":6146}],"how_diagnosis":[{"id":13727,"answer":"Clinical assessment","answer_other":"","report":6146},{"id":13728,"answer":"Imaging","answer_other":"","report":6146},{"id":13729,"answer":"PCR","answer_other":"","report":6146}],"author_username":"Parvesh Paul","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"Christian Medical College, Ludhiana, Punjab, India.","author_country":"India","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4149,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6146}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[{"id":372,"answer":"White","answer_other":""}],"created":"2020-09-29T17:48:44.623204Z","updated":"2020-10-04T23:52:09.651100Z","title":"Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32474988,"doi":"10.1111/dth.13708","article_url":"https://pubmed.ncbi.nlm.nih.gov/32474988/","pub_year":2020,"published_authors":"Valenti M\r\nFacheris P\r\nPavia G\r\nGargiulo L\r\nBorroni RG\r\nCostanzo A\r\nNarcisi A","article_author_email":"Author email could not be found.","journal":"Dermatologic therapy","abstract":"We present the case of a 57-year-old male patient with a 9 years history of psoriasis and psoriatic arthritis treated with 40 mg subcutaneous adalimumab every two weeks since June 2018, that rapidly recovered from COVID-19.","article_type":"Original","study_type":"Case Report","number_of_patients":1,"article_patient_number":"","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"51-60 years","sex":"Male","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Psoriasis, psoriatic arthritis and hyperhomocysteinemia","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"40 mg subcutaneous adalimumab every two weeks since June 2018\r\nThe patient suffered from arterial hypertension under therapy with 160 mg daily of oral Valsartan and hyperhomocysteinemia. \r\nThree days after the last scheduled administration of adalimumab, the patient developed fever (up to 38.8Â° C), malaise and anosmia.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[5711,6675]}]